Amantadine Therapy for Cognitive Impairment in Long COVID (AmantadineLC)

Amantadine Therapy for Cognitive Impairment Related to Post-COVID Condition

This study will look at the effects of amantadine on cognitive function in persons with Long COVID. It will also collect specimens to study possible causes of cognitive symptoms in Long COVID, and whether any lab tests can predict who will respond better to amantadine.

Study Overview

• Status: Recruiting
• Conditions: Post-Acute COVID19 Syndrome; Long COVID; Post-COVID19 Condition
• Intervention / Treatment: Drug: Amantadine

Detailed Description

This study will enroll 60 subjects with Long COVID and cognitive symptoms such as problems with memory, concentration, speech and attention, and "brain fog." Subjects will be assigned randomly to two groups. One group will be treated with amantadine, the other group will receive placebo. The study will last 4 months. During that time, subjects will be assessed at regular intervals with symptom questionnaires, cognitive tests, and lab measurements.

• Study Type: Interventional
• Enrollment (Estimated): 60
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Andrew I Schamess, MD; Phone Number: (614) 688-6470; Email: andrew.schamess@osumc.edu
• Study Contact Backup: Name: Seuli Brill, MD; Phone Number: (614) 293-8054.; Email: seuli.brill@osumc.edu

Study Locations

• United States
  • Ohio
    • Columbus, Ohio, United States, 43221
      • Recruiting
      • The Ohio State University Medical Center
      • Contact: Tait Palm, B.S.; Phone Number: 614-293-8054; Email: tait.palm@osumc.edu
      • Principal Investigator: Andrew I Schamess, MD
      • Principal Investigator: Seuli Brill, MD
      • Sub-Investigator: Bowman-Burpee Susan, RN
      • Sub-Investigator: Oltz Eugene, Ph.D.
      • Sub-Investigator: Gumina Richard, MD
      • Sub-Investigator: Shan-Lu Liu, PhD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. 18 years of age and above at the signing of informed consent
2. Had a positive laboratory or home test for COVID19 within one year prior to signing of informed consent, with subsequent symptoms meeting criteria for PASC.
3. Subjective Cognitive impairment associated with PASC
4. Cognitive symptoms will be formally assessed at a pre-enrollment visit using the PROMIS Cognitive Function Questionnaire (CGQ) and the PROMIS Cognitive Abilities subset (CAS), which are validated patient-reported measures of subjective cognitive functioning. Potential participants must have a cumulative score less than 60 (indicating at least mild subjective cognitive dysfunction) to be eligible.
5. Is willing and able to comply with study visits and study-related procedures/assessments.
6. Is able to provide informed consent to participate in the study 5.
7. Is not currently taking a medication with adverse interactions with amantadine. (Table 2)
8. If the participant is of child bearing potential, , is not pregnant at enrollment based on negative urine pregnancy test.
9. If the participant is of child-bearing potential, is consistently using one or more forms of prescribed birth control, such as an oral contraceptive, intrauterine device or a long-acting reversible contraceptive.
10. Is not breastfeeding.
11. Is willing to abstain from alcohol use for the duration of the study.
12. Endorses self-reported cognitive impairment on the PROMIS CF[40].
13. Does not have any other contraindications to amantadine use as noted in section 6 below or as identified by the study clinician investigators.

Exclusion Criteria:

1. At risk for complications of study drug with conditions such as:

   • Lifetime history of compulsive or impulsive behavior: Compulsive gambling, hypersexuality, binge eating; suicidality.
   • Underweight, malnourished at time of enrollment.
   • History of restrictive eating disorder within 3 months prior to consent.
   • Lifetime history of heart failure or diagnosed cardiac arrhythmia.
   • Untreated angle closure glaucoma at time of enrollment.
   • Lifetime history of psychosis or psychotic disorder.
   • Lifetime history of seizure disorder.
   • Known allergy to amantadine.
   • History of binge drinking, heavy alcohol use, or alcohol use disorder as defined by the National Institute on Alcohol Abuse and Alcoholism (NIAAA)[54] and the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)[55].
   • Use of kava-kava within 3 months prior to consent.
   • Breastfeeding at screening or expected to be breastfeeding during study period.
   • Pregnant at time of screening or expecting to become pregnant during the study period.
2. Is taking a medication that adversely interacts with amantadine (see Table 2)
3. Has any physical examination findings, and/or history of any illness, concomitant medications or recent live vaccines that, in the opinion of the study investigator, might confound the results of the study or pose an additional risk to the subject by their participation in the study.
4. Prior diagnosis of dementia, neurodegenerative disorder, multiple sclerosis or other autoimmune neurologic disorder, or cognitive impairment.
5. Enrolled in any other research study involving intervention for PASC.
6. If the individual is of child-bearing potential, is not consistently using one or more forms of prescribed birth control.
7. Is not willing to abstain from alcohol for the duration of the study.
8. Is not willing and able to adhere to study visits and study-related procedures/assessments.
9. Is not able to provide informed consent to participate in the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Single Group Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Amantadine; Subjects will be treated with amantadine.	Drug: Amantadine; Subjects will be give amantadine 100 mg twice daily.
Placebo Comparator: Placebo; Subjected received placebo identical to amantadine in appearance.	Drug: Amantadine; Subjects will be give amantadine 100 mg twice daily.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Improvement in cognitive symptoms	Improvement in scores on self-assessment of overall cognitive functioning	4 months
Improvement on objective cognitive testing	Subjects will be administered battery of cognitive tests to determine if there is a change in objective cognitive function	4 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Mood symptoms	Subjects will be administered anxiety and depression questionnaires to determine if there is improvement in mood symptoms.	4 months
Medication tolerability	Subjects will complete a questionnaire addressing tolerability of amantadine and side effects experienced	4 months

Collaborators and Investigators

• Sponsor: Ohio State University

Study record dates

Study Major Dates

• Study Start (Actual): December 7, 2023
• Primary Completion (Estimated): April 15, 2025
• Study Completion (Estimated): May 15, 2025

Study Registration Dates

• First Submitted: September 22, 2023
• First Submitted That Met QC Criteria: September 22, 2023
• First Posted (Actual): September 26, 2023

Study Record Updates

• Last Update Posted (Actual): March 7, 2024
• Last Update Submitted That Met QC Criteria: March 5, 2024
• Last Verified: March 1, 2024

More Information

Terms related to this study

• Keywords: cognition; long covid; amantadine; PASC; brain fog; post COVID condition
• Additional Relevant MeSH Terms: Mental Disorders; Pathologic Processes; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Pneumonia, Viral; Pneumonia; Lung Diseases; Neurocognitive Disorders; Disease Attributes; Cognition Disorders; Chronic Disease; Post-Infectious Disorders; COVID-19; Disease; Cognitive Dysfunction; Post-Acute COVID-19 Syndrome; Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Peripheral Nervous System Agents; Antiviral Agents; Analgesics; Sensory System Agents; Analgesics, Non-Narcotic; Dopamine Agents; Antiparkinson Agents; Anti-Dyskinesia Agents; Amantadine
• Other Study ID Numbers: 2023H0268; GF317855 (Other Grant/Funding Number: Private Donor)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: It is not yet known if there will be a plan to make IPD available.
• IPD Sharing Time Frame: Upon study completion
• IPD Sharing Access Criteria: As appropriate
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ICF; CSR

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No